VANCOUVER and MINNEAPOLIS, March 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the journal Clinical Cardiology has published an article entitled, “Long-term outcomes of patients undergoing coronary sinus reducer implantation – A multicenter study.” The article, authored by Maayan Konigstein, M.D., Tel […]
Other News
FibroGen Provides Regulatory Update on Roxadustat
SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold an advisory committee (AdCom) meeting to review the new drug application for […]
LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich’s Ataxia Gene Therapy Program (LX2006)
LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed from academic partners and data from Adverum’s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021 NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — LEXEO […]
CHF Solutions, Inc. Announces 49.5 Percent Increase in Revenue for Fourth Quarter 2020 and Provides Company Update
EDEN PRAIRIE, Minn., March 02, 2021 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter ended December 31, 2020. Recent Highlights Revenue for the fourth quarter of 2020 was $2 million, an increase of 49.5% compared to the prior year period Gross margin […]
Mesoblast Completes US$110/A$138 Million Financing Led by US Strategic Investor Group
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB) announced today it has entered into subscription agreements for a total of US$110 million via the issue of 60 million shares in a private placement led by a strategic US investor group (SurgCenter Development), at A$2.30 per share, […]
Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, […]
Liquidia Corporation Secures $20.5 Million Debt Facility with Silicon Valley Bank
RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the closing of a debt facility on February 26, 2021, with Silicon Valley Bank, which provides Liquidia with up to $20.5 million in term loans of which the first $10.5 million was funded at […]
Acutus Medical Appoints Duane Wilder as Chief Commercial Officer
Wilder brings deep expertise in Image Guided Therapy to help accelerate commercialization and market expansion efforts CARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Duane Wilder […]
Aziyo Biologics Reports Fourth Quarter and Full Year 2020 Financial Results
SILVER SPRING, Md., March 01, 2021 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2020. […]
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
• Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million • FDA to hold Advisory Committee Meeting on Roxadustat New Drug Application SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter […]